Vedanta announces start of phase 1a/1b, first-in-human, clinical trial of VE303, an oral microbiome therapeutic for the treatment of recurrent C. difficile infections
Vedanta announces start of phase 1a/1b, first-in-human, clinical trial of VE303, an oral microbiome therapeutic for the treatment of recurrent C. difficile infections
We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.
Toggle navigation